α－CD_3单克隆抗体对肿瘤特异性T细胞的扩增和杀瘤活性的影响  

EFFECT OF ANTI-CD_3 MONOCLONAL ANTIBODY ON EXPANSION AND ANTI-TUMOR ACTIVITY OF TUMOR SPECIFIC T CELLS

作　　者：俞红[1] 黄辉[1] 林云璐[1] 

机构地区：[1]上海医科大学基础医学院免疫学教研室

出　　处：《上海医科大学学报》1996年第2期83-86,共4页Journal of Fudan University(Medical Science)

基　　金：国家自然科学基金

摘　　要：为寻找更有效的肿瘤过继性免疫治疗的方案，用α－ＣＤ３单克隆抗体（单抗）激活ＦＢＬ－３红白血病肿瘤细胞免疫的小鼠脾细胞获取肿瘤特异性Ｔ细胞，并观察α－ＣＤ３单抗对肿瘤特异性Ｔ细胞的增殖、杀瘤活性及表型的影响。体外实验结果显示，免疫小鼠脾细胞经α－ＣＤ３单抗激活后，采用低剂量ＩＬ－２即可维持其长期高度的、持续的增殖；又培养过程中α－ＣＤ３单抗持续存在可大大促进其对肿瘤的特异性杀伤。细胞分型分析结果也支持了α－ＣＤ３单抗的持续存在对维持肿瘤特异性Ｔ细胞的抗瘤活性具有很重要的意义，是肿瘤过继免疫疗法中颇有前景的治疗方案。PURPOSE The changes on cell expansion and anti-tumor activity of mouse tumor-specific T cells activated by anti-CD3 monoclonal antibody(McAb) were investigated.The goal of this study is to find out more efficient method for tumor adoptive immunotherapy.METHODS Tumor-specific T cells from tumor-immunized mice were obtained by in vitro activation of anti-CD3 monoclonal antibody.The changes on cell expansion and anti-tumor activity as well as phenotype were studied.Four different culture modes were applied in this experiment:(1) cultured in anti-CD3 McAb alone(anti-CD3 group);(2) cultured in 20 000u/L rIL-2 alone(IL-2 group);(3) activated by anti-CD3 McAb for 48 hr and then cultured in 20 000u/L rIL-2 alone(CD3-IL-2 group);(4) activated by anti-CD3McAb for 48 hr and then cultured in CD3 McAb plus 20 000u/L rIL-2(CD3+IL-2 group).RESULTS The cells in CD3-IL-2 group and CD3+IL-2 group increased and expanded 780 folds and 610 folds respectively within 20 day.The maximum anti-tumor activities of both groups were 41.8% and 91.8% respectively on day 12.However,the continuous use of anti-CD3 McAb alone had neither proliferative effect nor anti-tumor activity.The IL-2group maintained a low level of proliferation within 20 days and showed its maximum anti-tumor activity of 30.2% on day 12.The study of cell phenotype by FACS analysis on day 6 indicated that>98% effective cells of both the CD3-IL-2 group and CD3+IL-2 group were Thy1.2+ cells.On day 20 Thy1.2+ cells of CD3+IL-2 group was still 98.8% while Thy1.2+ cell of CD3-IL-2 group was only 44.4%.There were also differences in CD4+ and CD8+ between the 2 groups.CONCLUSIONS The tumor-specific T cells cultured in the presence of the combination of anti-CD3 McAb and low dosed rIL-2 may facilitate a rapid expansion and long term maintenance of higher cytotoxicity.In general,this is a promising approach in tumor adoptive immunotherapy.

关 键 词：抗CD3 单克隆抗体 肿瘤 T细胞 过继性免疫疗法 

分 类 号：R730.3[医药卫生—肿瘤]